Aller au contenu principal
Retour à l'annuaire
EV
Rhumatologue

Professeur ERIC VIGNON

RPPS 10003025664
Enseignement
📊 Reconnaissance scientifique : 33/100📝 76 articles publiés📚 HAL (2)🎓 6 thèses dirigées

✨ Profil synthétique

IA · 06/05/2026

Le Professeur Eric Vignon est un rhumatologue avec une expertise reconnue dans le domaine de la recherche sur l'ostéoarthrose, les troubles du genou et du hanche, ainsi que les traitements anti-inflammatoires. Ses travaux de recherche, avec un h-index de 33 et 76 publications, couvrent notamment les essais cliniques, les revues générales et les biothérapies. Il a également étudié les effets des AINS et des anti-TNF dans le traitement des maladies rhumatismales.

Expertises présumées

  • Ostéoarthrose
  • Prothèse du genou
  • Traumatologie du genou
  • Lupus érythémateux
  • Thérapies anti-TNF
  • Biothérapies non anti-TNF
  • Traitement des douleurs inflammatoires
  • Essais cliniques en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Direction de thèses

🎓 6 thèses dirigées

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

33

h articles cités ≥ h fois chacun. Un h de 33 = 33 publications avec 33+ citations.

Citations

4 277

Publications

76

i10-index

52

Thématiques principales

  • Osteoarthritis Treatment and Mechanisms ×52
  • Total Knee Arthroplasty Outcomes ×27
  • Hip disorders and treatments ×13
  • Knee injuries and reconstruction techniques ×11
  • Inflammatory mediators and NSAID effects ×10

Affiliations FR : Université Claude Bernard Lyon 1

Voir sur OpenAlex ↗

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

    Arthritis and rheumatism · 2010

    📚 306 citations🎯 RCR 8.99Top 3% NIH
    Lire l'abstract Crossref ↓

    AbstractObjectiveA number of open‐label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off‐trial patients with SLE seen in regular clinical practice.MethodsWe analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX.ResultsOne hundred thirty‐six patients received treatment for SLE. The mean ± SD score on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was 11.3 ± 8.9 at baseline. Severe infections were noted in 12 patients (9%), corresponding to a rate of 6.6/100 patient‐years. Most severe infections occurred within the first 3 months after the last RTX infusion. Five patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). Overall response was observed in 80 of 113 patients (71%) by the SELENA–SLEDAI assessment. Efficacy did not differ significantly between patients receiving RTX monotherapy and those receiving concomitant immunosuppressive agents (who had higher baseline disease activity). Articular, cutaneous, renal, and hematologic improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Among responders, 41% experienced a relapse of disease, with a response in 91% after retreatment with RTX.ConclusionData from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE. The contrasting results with those from recent RCTs leave open the question of the therapeutic use of RTX in SLE. Additional controlled studies with new designs are needed to define the place of RTX in the therapeutic arsenal for SLE.

  • 2
    Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial

    Arthritis and rheumatism · 2005

    📚 187 citations🎯 RCR 6.03Top 6% NIH🩺 Clinique
    Lire l'abstract Crossref ↓

    AbstractObjectiveTo determine whether chondroitin sulfate (CS) is effective in inhibiting cartilage loss in knee osteoarthritis (OA).MethodsIn this randomized, double‐blind, placebo‐controlled trial, 300 patients with knee OA were recruited from an outpatient clinic, from private practices, and through advertisements. Study patients were randomly assigned to receive either 800 mg CS or placebo once daily for 2 years. The primary outcome was joint space loss over 2 years as assessed by a posteroanterior radiograph of the knee in flexion; secondary outcomes included pain and function.ResultsOf 341 patients screened, 300 entered the study and were included in the intent‐to‐treat analysis. The 150 patients receiving placebo had progressive joint space narrowing, with a mean ± SD joint space loss of 0.14 ± 0.61 mm after 2 years (P = 0.001 compared with baseline). In contrast, there was no change in mean joint space width for the 150 patients receiving CS (0.00 ± 0.53 mm; P not significant compared with baseline). Similar results were found for minimum joint space narrowing. The differences in loss of joint space between the two groups were significant for mean joint space width (0.14 ± 0.57 mm; P = 0.04) and for minimum joint space width (0.12 ± 0.52 mm; P = 0.05). CS was well tolerated, with no significant differences in rates of adverse events between the two groups.ConclusionWhile there was no significant symptomatic effect in this study, long‐term treatment with CS may retard radiographic progression in patients with OA of the knee. However, the clinical relevance of the observed structural results has to be further evaluated, and further studies are needed to confirm the structural effects of CS.

  • 3
    Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS)

    Joint bone spine · 2006

    📚 155 citations🎯 RCR 5.93Top 6% NIH

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal41

▼

Essai clinique3

▼

Revue générale2

▼

AINS1

▼

Anti-TNF1

▼

Biothérapies non-anti-TNF1

▼

Lupus1

▼

Pharmacovigilance1

▼

Revue / méta-analyse1

▼

Vraie vie / RWE1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.